Revolutionary drug used to treat coronavirus is NOT part of Oxford University trial

A revolutionary antiviral drug that helps critically ill patients recover from a coronavirus within a week is not part of a drug trial by the University of Oxford to find a treatment, it emerged.

Remdesivir, made by pharmaceutical giant Gilead Sciences, has been tested in the United States and smaller trials in the United Kingdom led by Gilead itself, in which some critically ill patients have recovered fairly quickly to be removed from fans within 24 hours.

Gilead said yesterday that more than 100 patients have been recruited to test the drug at 15 NHS centers and that the results are expected in a few weeks.

But speaking on BBC Radio 4 this morning, Professor Peter Horby, who runs the UK drug recovery trial at Oxford University, said the drug was not part of the country’s tests .

In the United States, at the University of Chicago Medicine, 125 people with COVID-19 have been recruited into global clinical trials for the drug. Among these people, 113 suffered from a serious illness.

All patients were treated with daily infusions of remdesivir, an experimental drug touted for the first time to treat Ebola that has been in the making for ten years.

Most patients were discharged after their symptoms had subsided for a week, and only two patients died.

The drug remdesivir, manufactured by the pharmaceutical giant Gilead Sciences, has been the subject of trials in the United States and smaller trials in the United Kingdom led by Gilead itself (photo, a bottle of the drug Remdesivir)

The drug remdesivir, manufactured by the pharmaceutical giant Gilead Sciences, has been the subject of trials in the United States and smaller trials in the United Kingdom led by Gilead itself (photo, a bottle of the drug Remdesivir)

Professor Horby said, “So this drug is undergoing a number of trials. There is a trial that has just ended in China and I think we will see the results soon enough and it is also in trials in the UK led by the pharmaceutical company and it is being tested in the United States. United. But this is not currently in our trial.

He added, “I think we have to be careful. But yes, it is a drug which, in the laboratory, seems to have a good activity. We therefore hope that it will have the same activity in people and patients. “

WHAT ARE THE THREE MAIN CORONAVIRUS TESTS IN THE UK?

Principle

The Principle trial studies people aged 50 to 64 who have symptoms of COVID-19 and a chronic health problem such as heart disease, asthma, and cancer.

It is not known how many patients participate.

It is also open to people 65 and over, with or without other illnesses.

The first drug to be tested is hydroxychloroquine, sold under the name of Plaquenil. Other potential treatments will be used if they show promise in preclinical studies.

The study is being conducted at the Research and Surveillance Center (RSC) of the Royal College of General Practitioners (RCGP) in Surrey.

It will last until March next year.

Recovery

The COV-id19 (RECOVERY) therapy randomized trial is conducted by the University of Oxford.

He will test the anti-HIV drug lopinavir / ritonavir, marketed under the names of Kaletra and Aluvia, hydroxychloroquine, a malaria drug sold under the name of Plaquenil, and dexamethasone, a type of steroid used in various conditions to reduce inflammation.

Almost 1,000 patients from 132 different hospitals have already been recruited in just 15 days.

Thousands more are expected to join the trial in the coming weeks, making it the largest randomized controlled trial of potential COVID-19 treatments in the world.

Definitive results on the safety and efficacy of treatments are expected within a few months and, if they are positive, they could potentially benefit hundreds of thousands of people around the world.

REMAP-CAP

The REMAP-CAP trial is an international effort involving more than 50 research teams from around the world.

He is specifically interested in patients who develop community-acquired pneumonia (CAP) as a result of viral infections.

The study will test 16 drugs, including hydroxychloroquine, lopinavir / ritonavir and interferon beta, all of which have shown promise in preclinical trials.

Between 2,000 and 4,000 patients will be enrolled.

The UK pharmaceutical program is called The Randomized Evaluation of COV-id19 thERapY (RECOVERY) trial and is the world’s largest single drug trial to treat coronavirus.

The university won the support of the chief medical officer of health, Professor Chris Whitty, and called on doctors across the country to enroll patients for the voluntary trial.

Volunteers have since joined the trial from more than 160 NHS trusts across the country and scientists hope more people will continue to register.

Doctors did not quantify the number of people the trial needs to be successful, but he said the more participants, the more likely the team would be able to find answers.

Participants will receive one of four drugs currently on the market – including the antimalarial drug presented by Donald Trump, known as hydroxychloroquine.

Other drugs considered treatment for COVID-19 include a combination of Lopinavir and Ritonavir (known by the brand name Kaletra), which is used to treat HIV; low-dose dexamethasone, a steroid used to reduce inflammation; and azithromycin, a commonly used antibiotic.

Professor Horby said: It has been implemented across the NHS at unprecedented speed. Currently, we are recruiting around 300 patients per day. Which is almost equivalent to one test a day. So we are breaking records here to try to find a cure as soon as possible.

However, interest in remdesivir has increased after successes around the world.

Dr. Kathleen Mullane, who is overseeing a trial of the drug at the University of Chicago, told The Times: “Most of our patients are severe and most go away at six days.

During the University of Chicago study, patients were treated with daily infusions of remdesivir, an experimental drug touted for the first time to treat Ebola that has been in the making for ten years.

Most patients were discharged after their symptoms had subsided for a week, and only two patients died.

The manufacturer – pharmaceutical giant Gilead Sciences – saw its shares rise 16% on Thursday afternoon as US equity markets rallied overnight in response to the encouraging results of the test.

There is currently no approved treatment for COVID-19, the highly contagious respiratory disease caused by the new coronavirus that has infected more than two million people worldwide.

Hopes have been placed on the remdesivir, but experts have encouraged cautious optimism about the early findings.

Remdesivir’s antiviral trial reports “quick cures” for severely coronavirus hospitalized patients, almost all of whom are discharged within a week. In the photo: a vial of remdesivir, an investigational drug, is visually inspected at a manufacturing site in Gilead, USA.

The University of Chicago is one of 152 sites participating in Gilead's Phase III clinical trial involving severe COVID-19 patients. Pictured is headquarters in Foster City, California

The University of Chicago is one of 152 sites participating in Gilead’s Phase III clinical trial involving severe COVID-19 patients. Pictured is headquarters in Foster City, California

Professor Peter Horby, who heads the UK drug recovery trial at Oxford University, said that remdesivir was not part of the country's tests

Professor Peter Horby, who heads the UK drug recovery trial at Oxford University, said that remdesivir was not part of the country’s tests

Remdesivir is just an investigational drug, and it was initially hoped that it would help fight Ebola. But it has weakened compared to other drugs.

He was honored once again after the World Health Organization ranked him as “the most promising candidate” for COVID-19 therapy in January.

The drug has been shown to stop other similar coronaviruses, including MERS, in animal studies.

And the first COVID-19 patient diagnosed in the United States reportedly improved overnight after doctors gave the 35-year-old remdesivir as a last attempt to treat it.

Scientists say that remdesivir – which is also being tested in many UK hospitals – could have a “profound impact” on the global pandemic.

The University of Chicago is one of 152 sites participating in Gilead’s Phase III clinical trial involving severe COVID-19 patients, along with other sites in the United Kingdom.

This is a “single arm” study, which means it does not measure the drug compared to a group of matched patients treated with a placebo.

Remdesivir was honored once again after the World Health Organization ranked it “the most promising candidate” for COVID-19 treatment in January. In the photo is a mock-up of a pill version, as it is currently only an experimental drug

The antiviral drug resulted in “rapid recovery from fever and respiratory symptoms”, “almost all the patients having been discharged in less than a week”. Picutred: a vial of remdesivir at a press conference at Eppendorf University Hospital in Hamburg, Germany, April 8

UChicago Medicine has recruited 125 people with COVID-19 in two Gilead phase 3 clinical trials, according to the Medical News website STAT.

Among these people, 113 suffered from a serious illness. All patients were treated with daily infusions of remdesivir.

WHAT IS REMDESIVIR?

Remdesivir was developed about 10 years ago to destroy the Ebola virus. However, it was ruled out when other better candidates emerged.

It is manufactured by the California pharmaceutical company Gilead Sciences, the company behind the life-changing anti-HIV pill, Truvada, or PrEP. Because it is only an investigational drug, it has no name on the market.

Laboratory tests for remdesivir have shown promise against coronaviruses – but human trials are still in their infancy.

Doctors in the United States have tried it on patients and it has accelerated recovery from the first person treated for the virus.

The 35-year-old man in Washington State near Seattle – whose infection was announced on January 20 – recovered after receiving the drug.

A California woman who doctors say is going to die, also recovered in the United States after receiving the drug.

Four American passengers aboard the Diamond Princess cruise ship treated with drugs in Japan also recovered.

Officials in Liguria – a coastal region of Italy – also announced that an infected 70-year-old man has recovered and may return home after 12 days in hospital.

It is not prescribed on the NHS because it has not been approved.

Hundreds of patients – including some in the UK – participating in a European mega-trial will have the chance to take the drug to prove whether it can fight the coronavirus.

The drug is also being tested on patients with coronaviruses in China and at the University of Nebraska.

Scientists are hopeful because the drug has been proven to be safe for humans. But its side effects are still not well understood.

Professor Devi Sridhar, President of Global Public Health at the University of Edinburgh, hailed remdesivir as “one of the most promising antivirals” under investigation.

While Dr. Alfredo Garzino-Demo, of the University of Maryland medical school, said the evidence shows that he has the ability to treat COVID-19 patients.

The antiviral drug resulted in “rapid recovery from fever and respiratory symptoms”, “almost all the patients having been discharged in less than a week”.

Most of them have now been discharged, although the vast majority are seriously ill at the start and two patients have died.

The results were revealed by Kathleen Mullane, an infectious disease specialist overseeing remdesivir studies for the hospital, during a videoconference, a copy of which STAT obtained.

“ The anecdotal evidence … looks promising at first glance and continues to support some potential for the drug to be active in some COVID-19 patients, ” RBC Capital Markets analyst Brian Abrahams said in a statement. research note.

“Nevertheless, there are major limits to the contextualization and interpretation of these data.”

Interest in Gilead’s drug in the midst of the ongoing coronavirus pandemic has been high.

Last week, the New England Journal of Medicine published an analysis showing that two-thirds of a small group of critically ill COVID-19 patients improved after treatment with remdesivir.

The article author described the results as hopeful, but cautioned that it is difficult to interpret the results because they do not include comparison with a control group.

The number of patients was small, the details disclosed were limited and the follow-up time was relatively short.

Gilead, in an emailed statement, said that “all of the data must be analyzed in order to draw any conclusions from the test.”

UChicago Medicine, also in an email, said that “partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions”.

The university said that information from an internal forum for research colleagues regarding the work in progress had been published without permission.

Gilead expects the results of its phase 3 study in patients with severe COVID-19 by the end of this month, and that additional data from other studies will be available in May.

The company’s severe COVID-19 study includes 2,400 participants from 152 different clinical trial sites worldwide.

British patients will also be enrolled, with 15 NHS trusts in London, Liverpool, Sheffield, Glasgow and Plymouth.

Another Gilead trial in patients with moderate COVID-19 symptoms includes 169 study sites.

It is the world's largest trial of drugs to treat coronavirus, which has killed more than 13,000 people in Britain and nearly 150,000 worldwide. it will be led by the University of Oxford and includes four potential treatments, one of which is hydroxychloroquine

It is the world’s largest trial of drugs to treat coronavirus, which has killed more than 13,000 people in Britain and nearly 150,000 worldwide. it will be led by the University of Oxford and includes four potential treatments, one of which is hydroxychloroquine

REMDESIVIR PREVENTS SEA CORONAVIRUS IN APES

Remdesivir has recently been shown to be effective in preventing disease and reducing the severity of symptoms in monkeys infected with MERS, an infection closely linked to SARS-CoV-2.

The results, reported in the Proceedings of the National Academy of Sciences in February, raised hopes that it could be effective against the new coronavirus.

“ It has not been successful with Ebola, but there are signs that it may be successful in coronaviruses, ” said Dr. Anthony Fauci, director of the United States National Institute of Allergies and Infectious Diseases ( NIAID) in a recent interview.

NIAID scientists tested remdesivir in monkeys 24 hours before infection with MERS and in other monkeys 12 hours after infection – the time period in monkeys when the virus is most active.

They were compared to untreated monkeys in a control group. After six days, all the untreated animals fell ill.

In monkeys treated before infection, the drug appeared to prevent disease. The animals in this group showed no signs of infection, had significantly lower virus levels in their lungs, and no lung damage.

Those treated after infection also performed better than the control group. The researchers found that they suffered from a less serious illness, that their lungs had lower virus levels, and that they had less severe lung damage.

Many successful drugs in monkeys fail in humans. Nevertheless, the researchers said their results raise hopes for ongoing studies in China and for compassionate use of the drug in critically ill patients.

Hilary Hutton-Squire, Vice-President and General Manager of Gilead Sciences UK and Ireland, said that Gilead started researching remdesivir more than ten years ago.

In animal trials, remdesivir has been shown to be “effective enough to prevent infection” and to reduce the severity of the diseases and lung damage caused by COVID-19.

This is according to Dr. Daniel Kuritzkes, chief of infectious diseases at the Brigham and Women’s Hospital in Boston, where research on remdesivir is underway.

Dr. Kuritzkes said: “It interferes with the enzyme that reproduces the genetic material of the virus.”

Previously, researchers from the University of North Carolina, Chapel Hill, have shown in test tube and animal studies that the drug can inhibit the coronaviruses that cause SARS and MERS.

And it got a spot in the World Health Organization’s big global trial, called SOLIDARITY, of four drugs.

The US National Institute of Allergy and Infectious Disease started a 800-patient trial in February that randomly assigns patients to treatment with remdesivir or a placebo. These results are not expected until after reading Gilead’s trial.

Remdesivir has been administered to several hundred critically ill COVID-19 patients in the United States, Europe and Japan under “compassionate use” arrangements.

For example, a young man from Snohomish County, Washington, the first COVID-19 patient in the United States, received remdesivir when his condition worsened.

He improved the next day, according to a case report published in The New England Journal of Medicine (NEJM). As of January 30, he had a mild cough.

But the “ compassionate use ” program was said to have been halted due to an unmanageable number of requests, he said on March 22.

The Dow Jones was up 3.08% at 4 a.m. ET

The Dow Jones was up 3.08% at 4 a.m. ET

Nasdaq was up 1.79% at 4:45 a.m.

Nasdaq was up 1.79% at 4:45 a.m.

The S&P was up 2.50% at 4:45 a.m.

The S&P was up 2.50% at 4:45 a.m.

President Donald Trump talks about the coronavirus in the James Brady Press Room of the White House. Trump says country is 'winning' war on coronavirus

President Donald Trump talks about the coronavirus in the James Brady Press Room of the White House. Trump says country is ‘winning’ war on coronavirus

BRITISH PATIENTS GET A REMDESIVIR

British coronavirus patients should receive remdesivir, a promising Ebola drug, as part of a trial amid the escalating crisis in the UK.

Remdesivir was quickly tested so that doctors in hospitals in England and Scotland could administer it to seriously ill COVID-19 patients.

Made by the pharmaceutical giant Gilead, remdesivir was originally supposed to help fight. But it has weakened compared to other drugs.

Gilead launched two randomized phase 3 studies to assess the safety and efficacy of remdesivir in patients with moderate to severe Covid-19. It will be administered via IV.

The lawsuit will involve thousands of people in 15 NHS trusts in London, Liverpool, Sheffield, Glasgow and Plymouth and more.

Critically, a clinical trial of this size will demonstrate the true effectiveness of remdesivir and any potential side effects.

Gilead shares, which closed at $ 76.54 in regular exchanges, rose 16% to $ 89.10 after hours.

First-rate futures indexes rose sharply following a wave of positive signals, paving the way for a decent trading day yesterday.

The Dow Jones rose 2.96%, the S&P rose 2.76% and the Nasdaq rose 1.97% at 4:30 am ET.

And Boeing, which floats stocks on the Dow Jones, helped boost the index after rising 8% overnight after announcing plans to resume production of planes at its Washington state plant .

But the increases made by the airline were half that of Gilead, which benefited from a publication in the media of the test laboratory.

The FTSE 100 also rebounded, up 193 points, and the European-wide Stoxx 600 index gained 2.9%.

The heavyweight index in London rose 3.4% to 5,822, barely a dozen points below its high point of the day.

Investor confidence was also boosted by Donald Trump unveiling White House directives to state governors to ease restrictions and restart the economy.

At the daily daily press conference, the President presented his plan “to preserve the health of our citizens, we must also preserve the health and functioning of our economy”.

Although he has conceded control of when the lock is lifted to the governors of each state, he has released a three-phase directive.

In the first phase, schools and youth activities must remain closed, but larger venues, including seated restaurants, cinemas, places of worship and sports venues may reopen under social distancing protocols.

Companies are also encouraged to allow workers to work from home as much as possible.

In phase two, teleworking is encouraged, but when workers return to the office, it is suggested that the common areas be closed.

In this phase, non-essential travel may also resume, bars may reopen, and gymnasiums will be allowed to operate.

In phase three, schools and activities for young people can reopen, visits to elderly care facilities and hospitals can resume. The sites can also take over the unrestricted allocation of the sites.

REVEALED: RECOVERY TEST DRUGS IN THE UK

Hydroxychloroquine

What are the branded versions of the drug?

Plaquenil.

What does it deal with?

Malaria, lupus and rheumatoid arthritis. It is a less potent and less toxic version of chloroquine phosphate, according to some experts.

Hydroxychloroquine, sold under the brand name Plaquenil, can treat COVID-19

Hydroxychloroquine, sold under the brand name Plaquenil, can treat COVID-19

Who makes it and where has it already been tested?

The pharmaceutical giant Sanofi has carried out a study on 24 patients, which the French government has described as “promising”.

French health authorities are now considering a larger trial of the drug, which is used on the NHS.

What do the studies show?

The results of the French study showed that three quarters of patients treated with the drug were cleared of the virus within six days. None of the placebo groups were treated.

How it works?

It interferes with viral molecules replicating in red blood cells.

Is it tested in the UK?

Hydroxychloroquine is one of the first drugs tested in the Principle study. That implies high risk primary care patients aged 50 to 64 with symptoms of COVID-19 and a chronic medical condition such as heart disease, asthma or cancer.

It is not known how many patients are participating, and the study will continue until March next year. It will therefore take some time before the results are clear.

The study is underway in the Nuffield Department of Primary Care Health Sciences at the University of Oxford.

Hydroxychloroquine would also be among the 1,000 drugs tested at Queens University in Belfast.

What are its side effects?

Skin rash, nausea, diarrhea and headache.

What do the experts think?

Chinese scientists investigating the other form of chloroquine wrote a letter to a prestigious newspaper saying that its “less toxic” derivative could also help.

Dans le commentaire de Cell Discovery – appartenant à l’éditeur Nature, ils ont déclaré qu’il partage des structures et des mécanismes chimiques similaires.

L’équipe d’experts a ajouté: “Il est facile d’évoquer l’idée que l’hydroxychloroquine peut être un candidat puissant pour traiter l’infection par le SRAS-CoV-2.”

Lopinavir / ritonavir

Quelles sont les versions de marque du médicament?

Kaletra et Aluvia.

Que traite-t-il?

Le lopinavir / ritonavir, commercialisé sous les marques Kaletra et Aluvia, est un médicament anti-VIH

Le lopinavir / ritonavir, commercialisé sous les marques Kaletra et Aluvia, est un médicament anti-VIH

Il s’agit d’un médicament anti-VIH administré aux personnes vivant avec le virus pour éviter qu’il ne se transforme en SIDA. Les patients infectés par le VIH ont reçu soit du Kaltra soit du ritonavir seul environ 1400 fois en 2018.

Qui le fait?

Le fabricant de l’Illinois AbbVie a fait don de fournitures gratuites du médicament aux autorités chinoises, américaines et européennes pour des tests.

Que montrent les études?

Les médias chinois ont rapporté que le médicament avait été utilisé avec succès pour soigner des patients atteints de coronavirus, mais les rapports n’ont pas été scientifiquement prouvés.

Une étude chinoise distincte publiée dans le New England Journal of Medicine a révélé que l’association lopinavir-ritonavir n’améliorait pas la survie ou la vitesse de récupération des patients COVID-19.

Cependant, les auteurs ont noté qu’ils avaient recruté une «population de patients gravement malades».

Dans une soumission d’essai clinique, des scientifiques sud-coréens ont déclaré que des études en laboratoire ont: «In vitro [laboratory] des études ont révélé que le lopinavir / ritonavir [has] activité antivirale contre le syndrome respiratoire aigu sévère coronavirus 2 (SARS-CoV-2). “

How it works?

Il s’agit d’une classe de médicaments appelés inhibiteurs de protéase, qui adhèrent essentiellement à une enzyme d’un virus qui est vitale pour la reproduction du virus.

Ce faisant, il bloque le processus normalement utilisé par le virus pour se cloner et propager l’infection.

Est-il testé au Royaume-Uni?

Il n’est pas prescrit sur le NHS pour les coronavirus car il n’a pas été approuvé – mais sera utilisé dans l’essai Recovery, une étude massive menée par l’Université d’Oxford pour les patients COVID-19 déjà hospitalisés.

L’essai a commencé à recruter des patients le 23 mars, dans le but d’atteindre les patients COVID-19 dans plus de 150 hôpitaux britanniques en deux semaines.

Le médicament est également testé sur des patients atteints de coronavirus en Chine et à l’Université du Nebraska.

Quels sont ses effets secondaires?

Les effets secondaires connus comprennent la diarrhée, des maux de tête, des maux d’estomac, une somnolence, des étourdissements, un mauvais goût dans la bouche et des troubles du sommeil.

Que pensent les experts?

Les médicaments ont été décrits comme «prometteurs» par les experts. Mais il y a eu une certaine hésitation au sujet de la combinaison de médicaments en raison de l’étude NEJM.

La dexaméthasone est un médicament stéroïdien utilisé pour traiter les allergies et l'asthme, ainsi que certains types de cancer

La dexaméthasone est un médicament stéroïdien utilisé pour traiter les allergies et l’asthme, ainsi que certains types de cancer

Dexaméthasone

Quelles sont les versions de marque du médicament?

Ozurdex et Baycadron.

Que traite-t-il?

Le stéroïde est utilisé pour traiter les allergies et l’asthme, ainsi que certains types de cancer.

Qui le fait?

Baycadron est fabriqué par Wockhardt Usa, Llc, tandis que Ozurdex est fabriqué par Allergan, le fabricant d’un implant mammaire texturé couramment utilisé.

Que montrent les études?

Aucune étude n’a encore prouvé que la dexaméthasone peut traiter le SRAS-CoV-2 – mais elle a été testée sur des patients atteints de MERS et de SRAS, deux coronavirus différents.

Une étude rétrospective de patients gravement malades atteints de MERS a révélé que près de la moitié des personnes qui ont reçu des stéroïdes avaient besoin de traitements supplémentaires tels qu’une assistance respiratoire, des médicaments pour augmenter la pression artérielle et une forme de dialyse.

Il a été constaté que les stéroïdes donnés prenaient plus de temps pour éliminer le virus de leur corps.

D’autres études ont révélé que le virus était toujours présent chez les patients atteints du SRAS qui ont pris les médicaments jusqu’à trois semaines après l’infection.

How it works?

Les stéroïdes sont souvent utilisés par les médecins pour réduire l’inflammation, qui est présente dans les poumons des patients atteints du coronavirus.

Cependant, les stéroïdes altèrent également la capacité du système immunitaire à combattre les virus et autres infections qui se développent souvent chez les patients atteints d’une maladie potentiellement mortelle.

Est-il testé au Royaume-Uni?

La dexaméthasone est l’un des médicaments utilisés dans l’essai RECOVERY lancé par l’Université d’Oxford. Il comprendra des patients dans plus de 130 hôpitaux du NHS à travers le Royaume-Uni.

Quels sont ses effets secondaires?

Le médicament est connu pour provoquer une augmentation de l’appétit et des brûlures d’estomac, ainsi qu’une faiblesse musculaire et de l’insomnie.

Que pensent les experts?

Dans un article de la prestigieuse revue médicale The Lancet, trois experts ont averti: “ Il n’existe aucune raison unique de s’attendre à ce que les patients infectés par le 2019-nCoV bénéficient de corticostéroïdes.

«Et ils pourraient être plus susceptibles d’être lésés par un tel traitement.

«Nous concluons que le traitement aux corticostéroïdes ne doit pas être utilisé pour le traitement d’une lésion ou d’un choc pulmonaire induit par le nCoV en dehors d’un essai clinique.»

L'azithromycine est un antibiotique qui a montré des signes de promesse lorsqu'il est utilisé en association avec l'hydroxychloroquine

L’azithromycine est un antibiotique qui a montré des signes de promesse lorsqu’il est utilisé en association avec l’hydroxychloroquine

Azithromycin

Quelles sont les versions de marque du médicament?

Z-Pack et Zithromax

Que traite-t-il?

Il est largement utilisé pour traiter les infections pulmonaires telles que la pneumonie, les infections du nez et de la gorge telles que les infections des sinus (sinusite), les infections cutanées, la maladie de Lyme et certaines infections sexuellement transmissibles.

L’azithromycine est utilisée chez les enfants, souvent pour traiter les otites ou les infections pulmonaires.

Who makes it?

Pfizer

What have studies shown?

Some clinicians have seen limited success in COVID-19 patients when adding it to chloroquine and/or hydroxycholoroquine.

There is little concrete evidence for this however and it remains a controversial topic.

Last month, big pharma firm Pfizer announced positive data for the use of its azithromycin (Zithromax) drug as a coronavirus treatment.

Hydroxychloroquine was given to 20 COVID-19 patients, and six also received azithromycin.

The rate of cure was highest in people who received hydroxychloroquine and azithromycin, the study reported.

How it works?

The drug itself is an antibiotic and therefore ineffective against viral infections.

However,  some experts think combining it with the old anti-malaria drugs can improve the prognosis for the sickest patients.

It is unknown how or if the drug itself can be effective against a virus directly.

Is it being tested in the UK?

Azithromycin is one of the four drugs featured in the University of Oxford’s Recovery Trial.

This programme currently ha more than 5,000 participants who are all coronavirus patients currently in British hospitals.

What are its side effects?

Common side effects include nausea, diarrhoea or vomiting, losing your appetite, headaches, dizziness or changes to taste.

More serious side effects which are far rarer include chest pains, yellowing skin/eye whites, tinnitus or vertigo.

What do the experts think?

Controversial scientists, such as French doctor Didier Raoult, claim the drug, iwhen used in partnership with hydroxychloroquine can help fight coronavirus.

However, experts are almost universally of the opinion that the antibiotic on its own will offer no protection from the viral infection.

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.